Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The mode of action for AMG133 is believed to involve this bispecific molecule simultaneously binding to both the GIP- and GLP-1 receptor, where it is demonstrated to increase cAMP production and induce internalization of co-localized GIP and GLP-1 receptors
GLP-1 medications were originally meant to be used for people who have problems with diabetes or obesity, but in recent years, they have become the fad for losing weight fast and efficiently
Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SO, et al
Providers often recommend a change in therapy if they believe another medication may provide better glycemic control or weight benefits
The development of GLP-/GIP dual agonists provides a more complete scheme for the treatment of metabolic diseases, but the safety of more dual agonists or multiple agonists in clinical trials is also worthy of attention
The primary mechanism of action involves: Stimulating insulin secretion in a glucose-dependent manner Suppressing glucagon release when blood glucose is elevated Slowing gastric emptying to promote satiety Acting on central nervous system pathways that regulate appetite For type 2 diabetes, these medications typically reduce hemoglobin A1c by 1.01.5%
